Cannabis compositions and methods

The pharmaceutical composition of any one of claims 3-8, in which the CBD and CBDA are present in the composition at a combined concentration of 1-20%.

The pharmaceutical composition of any one of claim 9, in which the CBD and CBDA are present in the composition at a combined concentration of 2.5%.

A pharmaceutical composition for inhalation by a subject comprising one or more cannabinoid in an acid form.

A pellet comprising compressed plant matter, the plant matter comprising:

• cannabidiol (CBD);
• and
• cannabidiolic acid (CBDA), wherein a least a portion of the CBDA remains in an acid form during consumption.

A pellet comprising cannabis plant matter, the cannabis plant matter formed into a pellet shape by compression.

Method of enhancing cannabidiolic acid (CBDA) in a pharmaceutical composition for inhalation.

A unit dosage form medicament for vaporization by a subject, the medicament comprising:

• a non-combustible substrate;
• and
• a cannabinoid in a neutral form embedded on the non-combustible substrate.

A vapor composition comprising a therapeutically effective dose of 6.6-8.1 mg of THC.

A composition for vaporization by a subject, the composition comprising:

• a non-combustible substrate;
• and
• a cannabinoid in a neutral form embedded on the non-combustible substrate.

Method of preparation of a unit dosage form medicament comprising a non-combustible substrate and a cannabinoid in a neutral form embedded on the non-combustible substrate, the method comprising:

• disbursing a liquid composition onto the non-combustible substrate, the liquid composition comprising the cannabinoid dissolved in a solvent;
• and
• drying the liquid composition to remove the solvent and embed the cannabinoid onto the non-combustible substrate.